Shin Ebihara

462 total citations
10 papers, 401 citations indexed

About

Shin Ebihara is a scholar working on Immunology, Dermatology and Rheumatology. According to data from OpenAlex, Shin Ebihara has authored 10 papers receiving a total of 401 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Immunology, 2 papers in Dermatology and 2 papers in Rheumatology. Recurrent topics in Shin Ebihara's work include Immunotherapy and Immune Responses (5 papers), Immune Cell Function and Interaction (4 papers) and Psoriasis: Treatment and Pathogenesis (3 papers). Shin Ebihara is often cited by papers focused on Immunotherapy and Immune Responses (5 papers), Immune Cell Function and Interaction (4 papers) and Psoriasis: Treatment and Pathogenesis (3 papers). Shin Ebihara collaborates with scholars based in Japan, United States and Canada. Shin Ebihara's co-authors include Kenichi Akiyama, Toshiyuki Takai, Akira Nakamura, Kazuhiko Takeda, Azusa Ujike, Kimio Matsumura, Setsuya Aiba, Toshihiro Nukiwa, Fumiko Date and Masao Ono and has published in prestigious journals such as Nature Immunology, The Journal of Immunology and Arthritis Research & Therapy.

In The Last Decade

Shin Ebihara

10 papers receiving 393 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shin Ebihara Japan 7 321 99 98 49 43 10 401
Bohdan P. Harvey United States 11 245 0.8× 107 1.1× 84 0.9× 44 0.9× 54 1.3× 20 411
Siska Wijngaarden Netherlands 7 185 0.6× 73 0.7× 119 1.2× 93 1.9× 37 0.9× 10 296
Toshibumi Shimokawa Japan 12 185 0.6× 149 1.5× 108 1.1× 27 0.6× 23 0.5× 23 330
Gitit Shahaf Israel 14 292 0.9× 109 1.1× 92 0.9× 16 0.3× 48 1.1× 20 411
Daniel Radtke Germany 10 273 0.9× 96 1.0× 37 0.4× 28 0.6× 37 0.9× 21 405
Olga Ignatovich United Kingdom 7 175 0.5× 187 1.9× 219 2.2× 33 0.7× 43 1.0× 12 366
Sun-Ok Yoon United States 10 283 0.9× 87 0.9× 26 0.3× 29 0.6× 58 1.3× 14 409
S. Goldberg United States 11 288 0.9× 124 1.3× 63 0.6× 25 0.5× 182 4.2× 15 439
Xiao-Tao Yao United States 6 136 0.4× 114 1.2× 92 0.9× 19 0.4× 132 3.1× 8 286

Countries citing papers authored by Shin Ebihara

Since Specialization
Citations

This map shows the geographic impact of Shin Ebihara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shin Ebihara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shin Ebihara more than expected).

Fields of papers citing papers by Shin Ebihara

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shin Ebihara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shin Ebihara. The network helps show where Shin Ebihara may publish in the future.

Co-authorship network of co-authors of Shin Ebihara

This figure shows the co-authorship network connecting the top 25 collaborators of Shin Ebihara. A scholar is included among the top collaborators of Shin Ebihara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shin Ebihara. Shin Ebihara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Katsuda, Yoshiaki, et al.. (2024). Pharmacological Properties of Tapinarof in Mice as a Novel Topical Agent for Plaque Psoriasis. 7(4). 116–122. 1 indexed citations
3.
Tao, Hai‐Yan, Scott M. Thacher, Kazuma Kobayashi, et al.. (2024). Pharmacological Properties of JTE-151; A Novel Orally Available RORγ Antagonist That Suppresses Th17 Cell-Related Responses <i>in Vitro</i> and <i>in Vivo</i>. Biological and Pharmaceutical Bulletin. 47(12). 2050–2057. 3 indexed citations
4.
Ebihara, Shin, et al.. (2023). Macrophage polarization toward M1 phenotype in T cell transfer colitis model. BMC Gastroenterology. 23(1). 411–411. 6 indexed citations
5.
Ebihara, Shin, et al.. (2016). Nuclear factor erythroid 2-related factor 2 is a critical target for the treatment of glucocorticoid-resistant lupus nephritis. Arthritis Research & Therapy. 18(1). 139–139. 34 indexed citations
6.
Ebihara, Shin, et al.. (2014). Interleukin-17 is a critical target for the treatment of ankylosing enthesitis and psoriasis-like dermatitis in mice. Autoimmunity. 48(4). 259–266. 35 indexed citations
8.
Akiyama, Kenichi, Shin Ebihara, Kimio Matsumura, et al.. (2003). Targeting Apoptotic Tumor Cells to FcγR Provides Efficient and Versatile Vaccination Against Tumors by Dendritic Cells. The Journal of Immunology. 170(4). 1641–1648. 87 indexed citations
9.
Ebihara, Shin, Kimio Matsumura, Shota Endo, et al.. (2003). Accelerated antigen presentation and elicitation of humoral response in vivo by FcγRIIB- and FcγRI/III-mediated immune complex uptake. Cellular Immunology. 225(1). 21–32. 77 indexed citations
10.
Ujike, Azusa, Kazuhiko Takeda, Akira Nakamura, et al.. (2002). Impaired dendritic cell maturation and increased TH2 responses in PIR-B−/− mice. Nature Immunology. 3(6). 542–548. 144 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026